Literature DB >> 8791198

Effects of dexamethasone and anabolic agents on proliferation and protein synthesis and degradation in C2C12 myogenic cells.

M M Desler1, S J Jones, C W Smith, T L Woods.   

Abstract

The objective of this experiment was to determine the dose response of dexamethasone (DEX) on C2C12 myogenic cells and to examine the effects of the anabolic compounds estradiol (E), testosterone (T), and dihydrotestosterone (D) alone and in combination with DEX on proliferation and protein turnover in cultured C2C12 myogenic cells. In the first study, cells were treated with seven concentrations (0, 25, 50, 75, 100, 150, or 200 nM) of DEX in medium with or without 5% horse serum (HS) for the determination of protein synthesis and degradation, and six concentrations (0, 50, 100, 150, 200, or 250 nM) of DEX in medium with 5% fetal bovine serum for cell proliferation measurements. Proliferation of myoblasts decreased (P < .05) with DEX. As DEX concentration increased, protein degradation in myotubes increased (P < .05) up to 100 nM, then declined. Protein synthesis decreased linearly (P < .01) as DEX concentration increased. The presence of HS in the medium decreased (P < .01) protein degradation by 32% as compared with no HS and increased (P < .05) protein synthesis. In the second study, cells were treated with E, T, or D at four concentrations (0, 100, 500, or 1,000 nM) in medium containing 0 or 100 nM DEX. Cells were assayed for protein synthesis or protein degradation. Synthesis decreased (P < .01) and degradation increased (P < .01) with DEX. No differences (P > .05) were found between E, T, or D hormone treatments or concentrations. To measure proliferation, myoblasts were treated 1 d after plating with the same anabolic hormone treatments in medium containing 0 to 100 nM DEX. Cells were grown to confluence and assayed for proliferation. Proliferation decreased (P < .01) in the presence of DEX in each treatment compared with controls. Cells treated with E had significantly lower (P < .05) proliferation rates than cells treated with T and D. The presence of concentrations of DEX at 100 nM inhibited proliferation and protein synthesis and increased protein degradation. Anabolic agents at pharmacological doses do not inhibit the DEX effects on C2C12 myogenic cells, nor do they directly affect proliferation or protein turnover.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8791198     DOI: 10.2527/1996.7461265x

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  16 in total

1.  Glucocorticoid inhibition of C2C12 proliferation rate and differentiation capacity in relation to mRNA levels of the MRF gene family.

Authors:  M F te Pas; P R de Jong; F J Verburg
Journal:  Mol Biol Rep       Date:  2000-06       Impact factor: 2.316

Review 2.  Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions.

Authors:  Vanessa Dubois; Michaël Laurent; Steven Boonen; Dirk Vanderschueren; Frank Claessens
Journal:  Cell Mol Life Sci       Date:  2011-11-19       Impact factor: 9.261

3.  β-Hydroxy-β-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophy.

Authors:  Zaira Aversa; Nima Alamdari; Estibaliz Castillero; Maurizio Muscaritoli; Filippo Rossi Fanelli; Per-Olof Hasselgren
Journal:  Biochem Biophys Res Commun       Date:  2012-06-13       Impact factor: 3.575

4.  A cell-autonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure.

Authors:  Monica L Watson; Leslie M Baehr; Holger M Reichardt; Jan P Tuckermann; Sue C Bodine; J David Furlow
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-21       Impact factor: 4.310

Review 5.  Growth Factors for Skeletal Muscle Tissue Engineering.

Authors:  Brian C Syverud; Keith W VanDusen; Lisa M Larkin
Journal:  Cells Tissues Organs       Date:  2016-11-09       Impact factor: 2.481

6.  Nonmyocytic androgen receptor regulates the sexually dimorphic development of the embryonic bulbocavernosus muscle.

Authors:  Lerrie Ann Ipulan; Kentaro Suzuki; Yuki Sakamoto; Aki Murashima; Yuuki Imai; Akiko Omori; Naomi Nakagata; Ryuichi Nishinakamura; Petr Valasek; Gen Yamada
Journal:  Endocrinology       Date:  2014-04-17       Impact factor: 4.736

7.  Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes.

Authors:  Michael Menconi; Patricia Gonnella; Victoria Petkova; Stewart Lecker; Per-Olof Hasselgren
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

8.  Effects of Dexamethasone on Satellite Cells and Tissue Engineered Skeletal Muscle Units.

Authors:  Brian C Syverud; Keith W VanDusen; Lisa M Larkin
Journal:  Tissue Eng Part A       Date:  2016-02-23       Impact factor: 3.845

9.  MicroRNA351 targeting TRAF6 alleviates dexamethasone-induced myotube atrophy.

Authors:  Jiaying Qiu; Lingbin Wang; Ye Wang; Qiuyu Zhang; Wenjing Ma; Qingqing Fang; Hualin Sun; Fei Ding
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

10.  DHA inhibits protein degradation more efficiently than EPA by regulating the PPARγ/NFκB pathway in C2C12 myotubes.

Authors:  Yue Wang; Qiao-wei Lin; Pei-pei Zheng; Jian-song Zhang; Fei-ruo Huang
Journal:  Biomed Res Int       Date:  2013-07-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.